ClinicalTrials.gg
CompletedNCT06465368Updated Jul 15, 2026Results posted

A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

A Phase 2 interventional study of PF-07220060 and letrozole in Breast Cancer, sponsored by Pfizer. Completed at 51 sites in 13 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing atirmociclib in Breast Neoplasms — 4 open to participants now, 8 under way, 2 of them phase 3. atirmociclib · Breast Neoplasms.

Enrollment
7th of 10
121 · median 262
Started
2024
with 2 others
Phase 2
4 of 10
2 open now
Registered
6th of 10
by date
Lead sponsor
7 of 10
Pfizer

Among the 10 studies testing atirmociclib in Breast Neoplasms, this one is the 7th largest by enrollment, is one of 3 that started in 2024, is one of 4 in phase 2, and was the 6th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 10 studies testing atirmociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About atirmociclib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing atirmociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the effects of the study medicine PF-07220060 plus letrozole, compared with the effects of taking letrozole alone without PF-07220060 for treatment of breast cancer.

This study is seeking for participants who are:

  • women of age 18 years and older post menopause (either naturally or surgically).
  • confirmed to have Hormone receptor (HR) positive, Human epidermal growth factor receptor 2 (HER2) negative breast cancer. HER2 negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2 negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface.
  • not been treated for their cancer before this study.

Participants will be randomly assigned (like flipping a coin) to receive the treatment (PF-07220060 plus letrozole) or letrozole alone. Both PF-07220060 and letrozole are taken by mouth. PF-07220060 will be taken twice a day for 14 days. Letrozole will be taken once a day for 14 days.

Participants will have a screening period for up to 28 days. If deemed fit, they will receive study treatment for 14 days, and then will have a follow-up visit about 28 days after their last dose.

All participants will have at least one biopsy during the study. Biopsy is the removal of cells or tissues for examining. All participants will have a biopsy on Day 14.

Additional assessments for safety including blood draws and interviews done by the site staff will be completed during the study.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • human epidermal growth factor receptor 2 (HER2)
  • hormone receptor (HR)
  • HER2-negative
  • HR-Positive
  • Breast Cancer (BC)
  • Neoadjuvant
  • Postmenopausal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with confirmed HR-positive and -negative BC (per local assessment)
  • Documented by estrogen receptor (ER) and/or progesterone receptor (PR)-positive disease by IHC or ISH
  • Participants must have Ki-67 score >/=10% with unilateral, invasive T1c-T4c, N0-N2, M0 BC
  • Participants must be willing and able to undergo a baseline and Day 14 and must have an PS or 0 or 1.
  • Participants must be treatment naive for the treatment of BC and cannot have had prior treatment with any systemic therapy (e.g., chemotherapy, hormonal therapy), radiation, surgery, or any agents or use of hormone replacement therapy (HRT) or any other estrogen-containing medication (including vaginal estrogen) within 2 weeks prior to diagnostic tissue sample taken.

Exclusion criteria

Exclusion Criteria:

  • No prior systemic therapy, radiation, surgery, therapy for treatment of breast cancer
  • Certain medical conditions in the previous 6 months, for example: myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure ( class III or IV), cerebrovascular accident, , symptomatic pulmonary embolism or other episode of thromboembolism
  • Lab abnormalities outside protocol specified parameters
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Arm A/Experimental/PF-07220060 plus letrozole

    PF-07220060 given as tablet by mouth twice a day for 14 days. Letrozole given as tablet by mouth once a day for 14 days.

    Drug: PF-07220060 · Drug: letrozole

  • Active comparator
    Arm B/Control/letrozole

    Letrozole given by mouth once a day for 14 days.

    Drug: letrozole

Interventions

  • PF-07220060 given as tablet by mouth twice a day for 14 days.

  • Letrozole given as tablet by mouth once a day for 14 days

    Also known as: Femara

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14

    CCCA was determined by antigen Kiel 67 (Ki-67) value as decided by Sponsor. Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry. Assessment at Day 14 was done in blinded manner by centrally assessed biopsy.

    Time frame: Day 14

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity and was congenital anomaly/birth defect. AEs that occurred on or after the first dose of study treatment and before the end of treatment (35 days after last dose of study treatment or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first) was considered TEAEs. All AEs (SAEs and all other AEs) were considered for evaluation.

    Time frame: From start of study intervention (Day 1) up to 35 days after the last dose of study intervention or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first (approximately up to 49 days)

  2. Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)

    An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity and was congenital anomaly/birth defect. AEs that occurred on or after the first dose of study treatment and before the end of treatment (35 days after last dose of study treatment or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first) was considered TEAEs.

    Time frame: From start of study intervention (Day 1) up to 35 days after the last dose of study intervention or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first (approximately up to 49 days)

  3. Number of Participant With AEs Leading to Any Study Intervention Discontinuation

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: During study treatment (maximum up to 14 days)

  4. Circulating Tumor Deoxyribonucleic Acid (ctDNA) Methylation Tumor Fraction Values at Baseline and Day 14

    The methylation-based tumor fraction of a single sample was estimated from methylation signals across targeted regions from the methylation panel, was calibrated using training data including cancer free donors and participants with mixed cancer types. The method included a data-informed differentially methylated region selection targeting regions with high pan cancer signal to noise ratio. This value was an estimate of the proportion of the sample that was tumor derived and expressed as percentage of DNA. ctDNA methylation tumor fraction values were reported in percentage at Baseline and Day 14 were assessed from central laboratory.

    Time frame: Baseline (the last measurement on or prior to date of the first dose of study intervention if the first dose is not missing, otherwise, on or prior to the randomization date), Day 14 (pre-dose)

  5. Plasma Concentration (Ctrough) of PF-07220060 on Day 14

    Ctrough was pre-dose plasma concentration.

    Time frame: Pre-dose (within 30 minutes before dosing) on Day 14

  6. Plasma Concentration at the Time of Biopsy (Cperi-biopsy) of PF-07220060 on Day 14

    Cperi-biopsy was plasma concentration at the time of biopsy.

    Time frame: Within 1 hour before or 1 hour after biopsy on Day 14

  7. Change From Baseline in Antigen Ki-67 at Day 14

    Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry and expressed as percentage of cells. Assessment at baseline and Day 14 was done in blinded manner by centrally assessed biopsy.

    Time frame: Baseline (the last measurement on or prior to date of the first dose of study intervention if the first dose was not missing, otherwise, on or prior to the randomization date), Day 14 (pre-dose)

  8. Relative Reduction (%) of Ki-67 From Baseline at Day 14

    Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry. Assessment at baseline and Day 14 was done in blinded manner by centrally assessed biopsy. Relative reduction at Day 14 was calculated as:100 \*(1-Ki-67 at Day 14/Ki-67 at Baseline). Relative reduction was expressed in percentage reduction.

    Time frame: Baseline (the last measurement on or prior to date of the first dose of study intervention if the first dose was not missing, otherwise, on or prior to the randomization date), Day 14 (pre-dose)

07

Results

Posted Jul 15, 2026

Participant flow

Treatment (up to 14 Days)
Participant flow — Treatment (up to 14 Days)
MilestonePF-07220060 + LetrozoleLetrozole Alone
Started5962
Completed5961
Not completed01
Withdrew: Other01
Follow-up (up to 35 Days Post Last Dose)
Participant flow — Follow-up (up to 35 Days Post Last Dose)
MilestonePF-07220060 + LetrozoleLetrozole Alone
Started5962
Completed5962
Not completed00

Outcome measures

PrimaryPercentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14

CCCA was determined by antigen Kiel 67 (Ki-67) value as decided by Sponsor. Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry. Assessment at Day 14 was done in blinded manner by centrally assessed biopsy.

Time frame:
Day 14
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14
Percentage of participantsPF-07220060 + LetrozoleLetrozole Alone
Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 1488.2 (76.6 to 94.5)17.9 (10.0 to 29.8)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity and was congenital anomaly/birth defect. AEs that occurred on or after the first dose of study treatment and before the end of treatment (35 days after last dose of study treatment or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first) was considered TEAEs. All AEs (SAEs and all other AEs) were considered for evaluation.

Time frame:
From start of study intervention (Day 1) up to 35 days after the last dose of study intervention or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first (approximately up to 49 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPF-07220060 + LetrozoleLetrozole Alone
Number of Participants With Treatment Emergent Adverse Events (TEAEs)2924
SecondaryNumber of Participants With Treatment Emergent Serious Adverse Events (TESAEs)

An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity and was congenital anomaly/birth defect. AEs that occurred on or after the first dose of study treatment and before the end of treatment (35 days after last dose of study treatment or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first) was considered TEAEs.

Time frame:
From start of study intervention (Day 1) up to 35 days after the last dose of study intervention or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first (approximately up to 49 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsPF-07220060 + LetrozoleLetrozole Alone
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)10
SecondaryNumber of Participant With AEs Leading to Any Study Intervention Discontinuation

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
During study treatment (maximum up to 14 days)
Reported as:
Count of participants · Participants
Number of Participant With AEs Leading to Any Study Intervention Discontinuation
ParticipantsPF-07220060 + LetrozoleLetrozole Alone
Number of Participant With AEs Leading to Any Study Intervention Discontinuation00
SecondaryCirculating Tumor Deoxyribonucleic Acid (ctDNA) Methylation Tumor Fraction Values at Baseline and Day 14

The methylation-based tumor fraction of a single sample was estimated from methylation signals across targeted regions from the methylation panel, was calibrated using training data including cancer free donors and participants with mixed cancer types. The method included a data-informed differentially methylated region selection targeting regions with high pan cancer signal to noise ratio. This value was an estimate of the proportion of the sample that was tumor derived and expressed as percentage of DNA. ctDNA methylation tumor fraction values were reported in percentage at Baseline and Day 14 were assessed from central laboratory.

Time frame:
Baseline (the last measurement on or prior to date of the first dose of study intervention if the first dose is not missing, otherwise, on or prior to the randomization date), Day 14 (pre-dose)
Reported as:
Median · Percentage of DNA
Circulating Tumor Deoxyribonucleic Acid (ctDNA) Methylation Tumor Fraction Values at Baseline and Day 14
Percentage of DNAPF-07220060 + LetrozoleLetrozole Alone
Baseline0.065 (0.007 to 5.171)0.047 (0.003 to 0.418)
Day 140.049 (0.008 to 0.397)0.036 (0.006 to 0.219)
SecondaryPlasma Concentration (Ctrough) of PF-07220060 on Day 14

Ctrough was pre-dose plasma concentration.

Time frame:
Pre-dose (within 30 minutes before dosing) on Day 14
Reported as:
Geometric mean · Nanogram per milliliter
Plasma Concentration (Ctrough) of PF-07220060 on Day 14
Nanogram per milliliterPF-07220060 + Letrozole
Plasma Concentration (Ctrough) of PF-07220060 on Day 14669.5 ± 39
SecondaryPlasma Concentration at the Time of Biopsy (Cperi-biopsy) of PF-07220060 on Day 14

Cperi-biopsy was plasma concentration at the time of biopsy.

Time frame:
Within 1 hour before or 1 hour after biopsy on Day 14
Reported as:
Geometric mean · Nanogram per milliliter
Plasma Concentration at the Time of Biopsy (Cperi-biopsy) of PF-07220060 on Day 14
Nanogram per milliliterPF-07220060 + Letrozole
Plasma Concentration at the Time of Biopsy (Cperi-biopsy) of PF-07220060 on Day 14808.2 ± 54
SecondaryChange From Baseline in Antigen Ki-67 at Day 14

Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry and expressed as percentage of cells. Assessment at baseline and Day 14 was done in blinded manner by centrally assessed biopsy.

Time frame:
Baseline (the last measurement on or prior to date of the first dose of study intervention if the first dose was not missing, otherwise, on or prior to the randomization date), Day 14 (pre-dose)
Reported as:
Median · Percentage of cells
Change From Baseline in Antigen Ki-67 at Day 14
Percentage of cellsPF-07220060 + LetrozoleLetrozole Alone
Change From Baseline in Antigen Ki-67 at Day 14-30.120 (-96.79 to 14.66)-17.270 (-56.65 to 14.10)
SecondaryRelative Reduction (%) of Ki-67 From Baseline at Day 14

Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry. Assessment at baseline and Day 14 was done in blinded manner by centrally assessed biopsy. Relative reduction at Day 14 was calculated as:100 \*(1-Ki-67 at Day 14/Ki-67 at Baseline). Relative reduction was expressed in percentage reduction.

Time frame:
Baseline (the last measurement on or prior to date of the first dose of study intervention if the first dose was not missing, otherwise, on or prior to the randomization date), Day 14 (pre-dose)
Reported as:
Median · Percentage reduction
Relative Reduction (%) of Ki-67 From Baseline at Day 14
Percentage reductionPF-07220060 + LetrozoleLetrozole Alone
Relative Reduction (%) of Ki-67 From Baseline at Day 1497.277 (-33.98 to 99.80)72.414 (-139.88 to 98.28)

Adverse events

Collected over From start of study intervention (Day 1) up to 35 days after the last dose of study intervention or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first (approximately up to 49 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-07220060 + Letrozole0/59 (0%)1/59 (1.7%)21/59 (35.6%)
Letrozole Alone0/62 (0%)0/62 (0%)16/62 (25.8%)
Most frequent serious events
Most frequent serious events
EventPF-07220060 + LetrozoleLetrozole Alone
Post procedural haematomaInjury, poisoning and procedural complications1/590/62
Most frequent other events
Most frequent other events
EventPF-07220060 + LetrozoleLetrozole Alone
DiarrhoeaGastrointestinal disorders11/591/62
NauseaGastrointestinal disorders8/593/62
HeadacheNervous system disorders2/597/62
AstheniaGeneral disorders6/593/62
Hot flushVascular disorders2/596/62
ArthralgiaMusculoskeletal and connective tissue disorders4/594/62
FatigueGeneral disorders3/593/62

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PF-07220060 + LetrozoleLetrozole AloneTotal
Mean66.5 ± 7.164.2 ± 7.465.3 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)PF-07220060 + LetrozoleLetrozole AloneTotal
Female5962121
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-07220060 + LetrozoleLetrozole AloneTotal
Hispanic or Latino12820
Not Hispanic or Latino393978
Unknown or Not Reported81523
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-07220060 + LetrozoleLetrozole AloneTotal
American Indian or Alaska Native101
Asian235
Native Hawaiian or Other Pacific Islander000
Black or African American022
White494190
More than one race000
Unknown or Not Reported71623
08

Study locations

51 sites
  • Advocate Good Shepherd Hospital
    Barrington, Illinois 60010, United States
  • AMG -Crystal Lake
    Crystal Lake, Illinois 60014, United States
  • Advocate Lutheran General Hospital
    Park Ridge, Illinois 60068, United States
  • Advocate Medical Group
    Park Ridge, Illinois 60068, United States
  • Baylor College of Medicine Medical Center
    Houston, Texas 77030, United States
  • Baylor St. Luke's Medical Center
    Houston, Texas 77030, United States
  • Ben Taub General Hospital
    Houston, Texas 77030, United States
  • Harris Health System - Smith Clinic
    Houston, Texas 77054, United States
  • O'Quinn Medical Tower - McNair Campus
    Houston, Texas 77054, United States
  • START San Antonio
    San Antonio, Texas 78229, United States
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3052, Australia
  • Institut Jules Bordet
    Anderlecht, Bruxelles-capitale, Région de 1070, Belgium
  • UZ Leuven
    Leuven, Vlaams-brabant 3000, Belgium
  • Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer
    Rennes, Ille-et-vilaine 35042, France
  • Centre de Cancérologie du Grand Montpellier
    Montpellier, Languedoc-roussillon 34070, France
  • Institut de Cancérologie de l'Ouest
    Saint-Herblain, Loire-atlantique 44805, France
  • CHU de Saint-Etienne
    Saint Priest En Jarez, Pays de la Loire Region 42271, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, Rhône 69310, France
  • HCL, Centre Hospitalier Lyon Sud
    Saint-Genis-Laval, Rhône 69230, France
  • Gustave Roussy
    Villejuif, Val-de-marne 94800, France
  • CaritasKlinikum Saarbrücken St. Theresia
    Saarbrücken, Saarland 66113, Germany
  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
    Meldola, Emilia-Romagna 47014, Italy
  • Fondazione IRCCS San Gerardo dei Tintori
    Monza, Lombardy 20900, Italy
  • Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno
    Livorno, Tuscany 57124, Italy
  • Ospedale Antonio Perrino
    Brindisi, 72100, Italy
  • Azienda Ospedaliero Universitaria Maggiore della Carità
    Novara, 28100, Italy
  • AIDPORT Sp. z o.o.
    Skórzewo, Greater Poland Voivodeship 60-185, Poland
  • Pratia MCM Krakow
    Krakow, Lesser Poland Voivodeship 30-727, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
    Warsaw, Masovian Voivodeship 02-781, Poland
  • Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu
    Przemyśl, Podkarpackie Voivodeship 37-700, Poland
  • Nemocnica AGEL Komarno
    Komárno, Nitra Region 945 05, Slovakia
  • Narodny onkologicky ustav
    Bratislava, 833 10, Slovakia
  • Seoul National University Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 03080, South Korea
  • Hospital General Universitario de Elche
    Elche, Alicante 03203, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona [barcelona] 08035, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Catalunya [cataluña] 08041, Spain
  • Hospital Jerez de la Frontera
    Jerez de la Frontera, Cádiz 11407, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, Madrid, Comunidad de 28009, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Madrid, Comunidad de 28041, Spain
  • Hospital Clínico Universitario Virgen de la Arrixaca
    El Palmar, Murcia, Región de 30120, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, Málaga 29010, Spain
  • Hospital Universitario San Cecilio
    Granada, 18016, Spain
  • Hospital Universitario HM Sanchinarro
    Madrid, 28050, Spain
  • Sjukhuset I Gävle
    Gävle, Gävleborgs LÄN [se-21] 80187, Sweden
  • Akademiska sjukhuset
    Uppsala, Uppsala LÄN [se-03] 751 85, Sweden
  • Tumor Zentrum Aarau
    Aarau, Canton of Aargau 5000, Switzerland
  • University Hospital Basel
    Basel, Canton of Basel-City 4031, Switzerland
  • Kantonsspital Baden
    Baden, 5404, Switzerland
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • Mackay Memorial Hospital
    Taipei, 10449, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jul 2025, 11 months.

Results were first posted in Jul 2026, 1 year after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 11 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 18, 2024
StartActual
Jul 11, 2024
Primary completionActual
Jul 10, 2025
CompletionActual
Jul 10, 2025
Results first posted
Jul 15, 2026
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06465368
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 18, 2024
Start date
Jul 11, 2024
Primary completion
Jul 10, 2025
Completion
Jul 10, 2025
Results posted
Jul 15, 2026
Last update
Jul 15, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atirmociclib

Start the discussion